Additional Coverage:
Eli Lilly and Company anticipates seeking FDA approval for a new weight-loss pill by year’s end. The pharmaceutical giant announced promising Phase 3 clinical trial results for the oral GLP-1 receptor agonist. While the pill reportedly doesn’t achieve the same level of weight loss as injectable GLP-1 medications, medical experts believe it will offer a valuable alternative for individuals struggling with obesity.